Summary of Sanofi’s Information on High-Dose Flu Vaccine (Efluelda) for the Elderly
This document from Sanofi highlights the importance of influenza vaccination,especially with a high-dose vaccine,for the elderly population. Here’s a breakdown of the key information:
Key Message: Protecting the health of the elderly is a priority and responsibility for Sanofi. A vaccine adapted to their weakened immune systems, like the high-dose flu vaccine (efluelda), is crucial for prevention.
Why High-Dose for the Elderly?
* Immunosenescence: Elderly individuals experience a decline in immune function (immunosenescence), making them more vulnerable to flu and its complications.
* Increased Protection: High-dose vaccines are designed to counteract immunosenescence,providing a stronger immune response.
* Reduced Severity: They significantly reduce the risk of hospitalization, serious complications, and loss of autonomy.
Recommendations & Support:
* National Medical Authorities: Age-adapted flu vaccines, including high-dose, are recommended by national medical authorities.
* Priority Group: The high-dose vaccine is specifically recommended for people aged 60 and over, annually starting in October.
* SNMF Support: The Association of National Society of Family Medicine/General Medicine (SNMF) emphasizes the essential role of age-adapted formulas and recommends the high-dose vaccine as the first option for those 60+.
Impact of Influenza:
* Global Burden: 3-5 million flu cases and 290,000-650,000 respiratory-related deaths globally each year.
* Elderly at Risk: The majority of flu-related deaths occur in people aged 65 and over.
* Societal Impact: low vaccination rates impact productivity and strain healthcare systems.
About Efluelda (Sanofi’s High-Dose Vaccine):
* Potency: Contains 60 µg of hemaglutinin (ha) per viral stem – four times the amount in standard vaccines.
* Proven Effectiveness:
* 24.2% more effective at preventing infection compared to standard-dose vaccines.
* 64.4% lower hospitalization rate for influenza and pneumonia.
* Reduces severe complications beyond just the flu (based on a meta-analysis of 45 million seniors).
* Availability: Authorized in the EU sence October 2024 and in Romania since February 2025, available for the 2025-2026 flu season.
About Sanofi:
* A global biopharmaceutical company focused on research, development, and innovation, utilizing AI.
* Dedicated to improving lives and supporting sustainable progress through innovative drugs and vaccines.
* A meaningful player in the Romanian market, committed to providing valuable solutions for patients and the healthcare system.
In essence, Sanofi is positioning Efluelda as a superior option for flu vaccination in the elderly, backed by clinical evidence and supported by medical authorities. They emphasize the importance of adapting vaccination strategies to the specific needs of this vulnerable population.
